A federal district judge late this afternoon struck down, as arbitrary and capricious, HRSA's finding that Lilly's 340B contract pharmacy policies violate the 340B statute. However, the judge said that manufacturers should not be allowed to unilaterally impose conditions on the location and delivery of 340B drugs and sent the matter back to HRSA.
Breaking: Federal Judge Vacates HRSA’s May 17 Letter to Lilly on 340B Contract Pharmacies, Sends Matter Back to Agency
A federal district judge in Indianapolis late this afternoon set aside and vacated the federal government’s May 17 finding that drug manufacturer Eli Lilly’s denials of 340B ceiling prices when covered entities use contract pharmacies violates the 340B statute.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
